Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Evaluation of multiple comparison correction procedures in drug assessment studies using LORETA maps.

Alonso JF, Romero S, Mañanas MÁ, Rojas M, Riba J, Barbanoj MJ.

Med Biol Eng Comput. 2015 Oct;53(10):1011-23. doi: 10.1007/s11517-015-1315-6. Epub 2015 Jun 4.

PMID:
26040586
2.

Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study.

Bouso JC, González D, Fondevila S, Cutchet M, Fernández X, Ribeiro Barbosa PC, Alcázar-Córcoles MÁ, Araújo WS, Barbanoj MJ, Fábregas JM, Riba J.

PLoS One. 2012;7(8):e42421. doi: 10.1371/journal.pone.0042421. Epub 2012 Aug 8.

3.

Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.

Estévez JA, Moltó J, Tuneu L, Cedeño S, Antonijoan RM, Mangues MA, Clotet B, Domingo P, Puntes M, Barbanoj MJ, Valle M.

J Antimicrob Chemother. 2012 Aug;67(8):2013-9. doi: 10.1093/jac/dks152. Epub 2012 May 7.

PMID:
22566588
4.

Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial.

Hoever P, Dorffner G, Beneš H, Penzel T, Danker-Hopfe H, Barbanoj MJ, Pillar G, Saletu B, Polo O, Kunz D, Zeitlhofer J, Berg S, Partinen M, Bassetti CL, Högl B, Ebrahim IO, Holsboer-Trachsler E, Bengtsson H, Peker Y, Hemmeter UM, Chiossi E, Hajak G, Dingemanse J.

Clin Pharmacol Ther. 2012 Jun;91(6):975-85. doi: 10.1038/clpt.2011.370.

5.

4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects.

Caudevilla-Gálligo F, Riba J, Ventura M, González D, Farré M, Barbanoj MJ, Bouso JC.

J Psychopharmacol. 2012 Jul;26(7):1026-35. doi: 10.1177/0269881111431752. Epub 2012 Jan 9.

PMID:
22234927
6.

Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.

Dos Santos RG, Valle M, Bouso JC, Nomdedéu JF, Rodríguez-Espinosa J, McIlhenny EH, Barker SA, Barbanoj MJ, Riba J.

J Clin Psychopharmacol. 2011 Dec;31(6):717-26. doi: 10.1097/JCP.0b013e31823607f6.

PMID:
22005052
7.

Sex differences in sleep after a single oral morning dose of olanzapine in healthy volunteers.

Giménez S, Romero S, Gich I, Clos S, Grasa E, Antonijoan RM, Barbanoj MJ.

Hum Psychopharmacol. 2011 Oct;26(7):498-507. doi: 10.1002/hup.1232. Epub 2011 Sep 28.

PMID:
21953682
8.

Pharmacology of ayahuasca administered in two repeated doses.

Dos Santos RG, Grasa E, Valle M, Ballester MR, Bouso JC, Nomdedéu JF, Homs R, Barbanoj MJ, Riba J.

Psychopharmacology (Berl). 2012 Feb;219(4):1039-53. doi: 10.1007/s00213-011-2434-x. Epub 2011 Aug 13.

PMID:
21842159
9.

Characterization of the cerebral activity by time-frequency representation of evoked EEG potentials.

Clariá F, Vallverdú M, Riba J, Romero S, Barbanoj MJ, Caminal P.

Physiol Meas. 2011 Aug;32(8):1327-46. doi: 10.1088/0967-3334/32/8/021. Epub 2011 Jul 15.

PMID:
21765206
10.

Methodology for determining major constituents of ayahuasca and their metabolites in blood.

McIlhenny EH, Riba J, Barbanoj MJ, Strassman R, Barker SA.

Biomed Chromatogr. 2012 Mar;26(3):301-13. doi: 10.1002/bmc.1657. Epub 2011 Jun 28.

PMID:
21710581
11.

Waking and sleep electroencephalogram variables as human sleep homeostatic process biomarkers after drug administration.

Giménez S, Romero S, Mañanas MA, Barbanoj MJ.

Neuropsychobiology. 2011;63(4):252-60. doi: 10.1159/000321806. Epub 2011 Apr 13.

PMID:
21494053
12.

Gastrointestinal safety of triflusal solution in healthy volunteers: a proof of concept endoscopic study.

Antonijoan RM, Gich I, Azaro A, Sainz S, Balanzó J, Izquierdo I, Borja J, Donado E, Blanch I, Barbanoj MJ.

Eur J Clin Pharmacol. 2011 Jul;67(7):663-9. doi: 10.1007/s00228-011-1004-9. Epub 2011 Feb 16.

PMID:
21327422
13.

Safety assessment and pharmacodynamics of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers--a first-time-in-human single ascending dose study.

Rico S, Antonijoan RM, Gich I, Borrell M, Fontcuberta J, Monreal M, Martinez-Gonzalez J, Barbanoj MJ.

Thromb Res. 2011 Apr;127(4):292-8. doi: 10.1016/j.thromres.2010.12.009. Epub 2011 Jan 22.

PMID:
21257196
14.

Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.

Moltó J, Valle M, Miranda C, Cedeño S, Negredo E, Barbanoj MJ, Clotet B.

Antimicrob Agents Chemother. 2011 Jan;55(1):326-30. doi: 10.1128/AAC.01082-10. Epub 2010 Nov 15.

15.

Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine.

McIlhenny EH, Riba J, Barbanoj MJ, Strassman R, Barker SA.

Biomed Chromatogr. 2011 Sep;25(9):970-84. doi: 10.1002/bmc.1551. Epub 2010 Nov 5.

PMID:
21058415
16.

Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.

Moltó J, Valle M, Back D, Cedeño S, Watson V, Liptrott N, Egan D, Miranda C, Barbanoj MJ, Clotet B.

Antimicrob Agents Chemother. 2011 Jan;55(1):72-5. doi: 10.1128/AAC.00789-10. Epub 2010 Oct 11.

17.

Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study.

García-Gea C, Ballester MR, Martínez J, Antonijoan RM, Donado E, Izquierdo I, Barbanoj MJ.

Br J Clin Pharmacol. 2010 Jun;69(6):663-74. doi: 10.1111/j.1365-2125.2010.03648.x.

18.

Assessment of addiction severity among ritual users of ayahuasca.

Fábregas JM, González D, Fondevila S, Cutchet M, Fernández X, Barbosa PC, Alcázar-Córcoles MÁ, Barbanoj MJ, Riba J, Bouso JC.

Drug Alcohol Depend. 2010 Oct 1;111(3):257-61. doi: 10.1016/j.drugalcdep.2010.03.024. Epub 2010 Jun 15.

PMID:
20554400
19.

No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.

Donado E, Izquierdo I, Pérez I, García O, Antonijoan RM, Gich I, Solans A, Peña J, Morganroth J, Barbanoj MJ.

Br J Clin Pharmacol. 2010 Apr;69(4):401-10. doi: 10.1111/j.1365-2125.2009.03599.x.

20.

Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.

Moltó J, Valle M, Santos JR, Mothe B, Miranda C, Cedeño S, Negredo E, Yritia M, Videla S, Barbanoj MJ, Clotet B.

Antivir Ther. 2010;15(2):219-25. doi: 10.3851/IMP1519.

PMID:
20386077
21.

Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers.

Antonijoan RM, Rico S, Martínez-González J, Borrell M, Valcarcel D, Fontcuberta J, Barbanoj MJ.

Int J Clin Pharmacol Ther. 2009 Dec;47(12):726-32.

PMID:
19954711
22.

Drug effect on EEG connectivity assessed by linear and nonlinear couplings.

Alonso JF, Mañanas MA, Romero S, Hoyer D, Riba J, Barbanoj MJ.

Hum Brain Mapp. 2010 Mar;31(3):487-97. doi: 10.1002/hbm.20881.

PMID:
19894215
23.

A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation.

Barbanoj MJ, Ballester MR, Antonijoan RM, Puntes M, Gropper S, Santos B, Albet C, Guglietta A.

Clin Exp Pharmacol Physiol. 2009 May;36(5-6):469-77. doi: 10.1111/j.1440-1681.2008.05089.x. Epub 2008 Oct 8.

PMID:
19673928
24.

Comparison of repeated-dose pharmacokinetics of prolonged-release and immediate-release torasemide formulations in healthy young volunteers.

Barbanoj MJ, Ballester MR, Antonijoan RM, Gich I, Pelagio P, Gropper S, Santos B, Guglietta A.

Fundam Clin Pharmacol. 2009 Feb;23(1):115-25. doi: 10.1111/j.1472-8206.2008.00643.x.

PMID:
19267775
25.
26.

Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments.

García-Gea C, Martínez-Colomer J, Antonijoan RM, Valiente R, Barbanoj MJ.

J Clin Psychopharmacol. 2008 Dec;28(6):675-85. doi: 10.1097/JCP.0b013e31818b2091.

PMID:
19011437
27.

Ocular reduction in EEG signals based on adaptive filtering, regression and blind source separation.

Romero S, Mañanas MA, Barbanoj MJ.

Ann Biomed Eng. 2009 Jan;37(1):176-91. doi: 10.1007/s10439-008-9589-6. Epub 2008 Nov 5.

PMID:
18985453
28.

Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.

Moltó J, Barbanoj MJ, Miranda C, Blanco A, Santos JR, Negredo E, Costa J, Domingo P, Clotet B, Valle M.

Clin Pharmacokinet. 2008;47(10):681-92.

PMID:
18783298
29.

Influence of ocular filtering in EEG data on the assessment of drug-induced effects on the brain.

Romero S, Mañanas MA, Barbanoj MJ.

Hum Brain Mapp. 2009 May;30(5):1470-80. doi: 10.1002/hbm.20614.

PMID:
18548559
30.

A comparative study of automatic techniques for ocular artifact reduction in spontaneous EEG signals based on clinical target variables: a simulation case.

Romero S, Mañanas MA, Barbanoj MJ.

Comput Biol Med. 2008 Mar;38(3):348-60. doi: 10.1016/j.compbiomed.2007.12.001. Epub 2008 Jan 28.

PMID:
18222418
31.

Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers.

Barbanoj MJ, Riba J, Clos S, Giménez S, Grasa E, Romero S.

Psychopharmacology (Berl). 2008 Feb;196(2):315-26. Epub 2007 Nov 21.

PMID:
18030450
32.

Connectivity analysis of EEG under drug therapy.

Alonso JF, Mañanas MA, Romero S, Riba J, Barbanoj MJ, Hoyer D.

Conf Proc IEEE Eng Med Biol Soc. 2007;2007:6188-91.

PMID:
18003434
33.

Study of the EEG changes during the combined ingestion of alcohol and H1-antihistamines by using the wavelet transform.

Poza J, Caminal P, Vallverdú M, Hornero R, Romero S, Barbanoj MJ.

Conf Proc IEEE Eng Med Biol Soc. 2007;2007:23-6.

PMID:
18001879
34.

Quantitative evaluation of automatic ocular removal from simulated EEG signals: regression vs. second order statistics methods.

Romero S, Mañanas MA, Barbanoj MJ.

Conf Proc IEEE Eng Med Biol Soc. 2006;1:5495-8.

PMID:
17945904
35.

Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers.

Barbanoj MJ, Urbano G, Antonijoan R, Ballester MR, Valle M.

Neuropsychobiology. 2007;55(3-4):203-12. Epub 2007 Sep 17.

PMID:
17878744
36.
37.

A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction to histamine in healthy adults.

Antonijoan RM, García-Gea C, Puntes M, Valle M, Esbri R, Fortea J, Barbanoj MJ.

Clin Drug Investig. 2007;27(7):453-61.

PMID:
17563125
38.

Evaluation of an automatic ocular filtering method for awake spontaneous EEG signals based on independent component analysis.

Romero S, Mananas MA, Riba J, Morte A, Gimenez S, Clos S, Barbanoj MJ.

Conf Proc IEEE Eng Med Biol Soc. 2004;2:925-8.

PMID:
17271830
39.

Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice.

Moltó J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, Delavarga M, Fumaz CR, Barbanoj MJ, Clotet B.

Br J Clin Pharmacol. 2007 Jun;63(6):715-21. Epub 2007 Jan 12.

40.

Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers.

Giménez S, Clos S, Romero S, Grasa E, Morte A, Barbanoj MJ.

Psychopharmacology (Berl). 2007 Mar;190(4):507-16. Epub 2007 Jan 5.

PMID:
17205319
41.

Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.

Moltó J, Valle M, Blanco A, Negredo E, DelaVarga M, Miranda C, Miranda J, Domingo P, Vilaró J, Tural C, Costa J, Barbanoj MJ, Clotet B.

Clin Pharmacokinet. 2007;46(1):85-92.

PMID:
17201460
42.

Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.

Moltó J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, DelaVarga M, Fumaz CR, Barbanoj MJ, Clotet B.

Br J Clin Pharmacol. 2006 Nov;62(5):560-6.

43.

Clinical pharmacokinetics of dexketoprofen trometamol: recent studies.

Barbanoj MJ.

Methods Find Exp Clin Pharmacol. 2006 Jun;28 Suppl A:3-5. No abstract available.

PMID:
16801986
44.

Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor.

Trocóniz IF, Zsolt I, Garrido MJ, Valle M, Antonijoan RM, Barbanoj MJ.

Pharm Res. 2006 Jul;23(7):1533-42. Epub 2006 Jun 21.

PMID:
16783479
45.

Quantifying drug-drug interactions in pharmaco-EEG.

Barbanoj MJ, Antonijoan RM, Riba J, Valle M, Romero S, Jané F.

Clin EEG Neurosci. 2006 Apr;37(2):108-20. Review.

PMID:
16733942
46.

Pattern of use and subjective effects of Salvia divinorum among recreational users.

González D, Riba J, Bouso JC, Gómez-Jarabo G, Barbanoj MJ.

Drug Alcohol Depend. 2006 Nov 8;85(2):157-62. Epub 2006 May 23.

PMID:
16720081
47.

Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant.

Riba J, Romero S, Grasa E, Mena E, Carrió I, Barbanoj MJ.

Psychopharmacology (Berl). 2006 May;186(1):93-8. Epub 2006 Mar 31.

PMID:
16575552
48.

Influence of individual differences in the Behavioral Inhibition System and stimulus content (fear versus blood-disgust) on affective startle reflex modulation.

Caseras FX, Fullana MA, Riba J, Barbanoj MJ, Aluja A, Torrubia R.

Biol Psychol. 2006 Jun;72(3):251-6. Epub 2006 Jan 6.

PMID:
16406216
49.

Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.

Barbanoj MJ, García-Gea C, Antonijoan R, Izquierdo I, Donado E, Pérez I, Solans A, Jané F.

Hum Psychopharmacol. 2006 Jan;21(1):13-26.

PMID:
16389668
50.

Effects of tobacco smoking on the kinetics of the pupillary light reflex: a comparison between smokers and non-smokers.

Morte A, Benito L, Grasa E, Clos S, Riba J, Barbanoj MJ.

Neuropsychobiology. 2005;52(4):169-75. Epub 2005 Oct 10.

PMID:
16220022

Supplemental Content

Loading ...
Support Center